Avexa Ltd

Richmond, Australia

Avexa Ltd

Richmond, Australia

Time filter

Source Type

Metifiot M.,U.S. National Cancer Institute | Vandegraaff N.,Avexa Ltd | Maddali K.,U.S. National Cancer Institute | Naumova A.,U.S. National Cancer Institute | And 4 more authors.
AIDS | Year: 2011

Objective: In this study, we characterized elvitegravir activity in the context of raltegravir resistance mutations. DESIGN:: Using site-directed mutagenesis, we generated recombinant integrase proteins and viruses harboring raltegravir resistance mutation to assess the biochemical and cellular activity of elvitegravir in the presence of such mutants. Methods: Recombinant proteins were used in gel-based assays. Antiviral data were obtained with reporter viruses in a single-round infection using a luciferase-based assay. Results: Although main raltegravir resistance pathways involving mutations at integrase position 148 and 155 confer cross-resistance to elvitegravir, elvitegravir remains fully active against the Y143R mutant integrase and virus particles. Conclusion: In addition to favorable pharmacokinetics compared to raltegravir, our findings provide the rationale for using elvitegravir in patients failing raltegravir because of the integrase mutation Y143. © 2011 Wolters Kluwer Health - Lippincott Williams & Wilkins.


Patent
CAS Shanghai Institute of Organic Chemistry and AVEXA Ltd | Date: 2011-07-15

The present invention provides a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. A pharmaceutical composition or medicament comprising a compound of Formula I is also provided


Spencer J.,University of Greenwich | Patel H.,University of Greenwich | Callear S.K.,University of Southampton | Coles S.J.,University of Southampton | Deadman J.J.,Avexa Ltd
Tetrahedron Letters | Year: 2011

A library of pyridines and pyrimidines has been synthesised in excellent yields employing microwave and flow chemistry methodologies. Work-up bottlenecks have been facilitated substantially by the use of supported reagents and many of the final compounds have been studied in the solid state by single crystal X-ray diffraction. © 2011 Elsevier Ltd. All rights reserved.


Patent
AVEXA Ltd | Date: 2012-09-13

The present invention provides a compound of formula (I) or a pharmaceutically acceptable derivative, salt or prodrug thereof. The present invention further provides a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative, salt or prodrug thereof. Pharmaceutical compositions comprising a compound of formula (I) are also provided.


Patent
AVEXA Ltd | Date: 2010-04-23

The present invention provides a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. A pharmaceutical composition or medicament comprising a compound of Formula I is also provided.


Patent
AVEXA Ltd | Date: 2012-02-27

The present invention provides a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative, salt or prodrug thereof. A pharmaceutical composition or medicament comprising a compound of Formula I is also provided.


Patent
AVEXA Ltd | Date: 2012-11-15

The present invention provides a method of treating HIV-1 infection in a subject. The method comprises administering to the subject a combination of anti-HIV-1 agents wherein the combination comprises an effective dose of Apricitabine and an effective dose of Atazanavir.


Patent
Avexa Ltd | Date: 2014-07-30

The present invention provides a compound of formula (I) or a pharmaceutically acceptable derivative, salt or prodrug thereof. The present invention further provides a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative, salt or prodrug thereof. Pharmaceutical compositions comprising a compound of formula (I) are also provided.


The present invention relates to novel bicyclic pyrimidinone compounds and analogues thereof for the treatment of viral infections, particularly HIV infections.


Trademark
AVEXA Ltd | Date: 2010-06-08

Human pharmaceutical preparations and substances, namely, anti-infectives, anti-virals, oncologicals, agents for treatment of diseases and disorders of the central nervous system, agents for treatment of inflammatory diseases.

Loading Avexa Ltd collaborators
Loading Avexa Ltd collaborators